BACKGROUND: Rare TREM2 variants are significant risk factors for Alzheimer's disease (AD). METHODS: We used next generation sequencing of the whole gene (n = 700), exon 2 Sanger sequencing (n = 2634), p.R47H genotyping (n = 3518), and genome wide association study imputation (n = 13,048) to determine whether TREM2 variants are risk factors or phenotypic modifiers in patients with AD (n = 1002), frontotemporal dementia (n = 358), sporadic (n = 2500), and variant (n = 115) Creutzfeldt-Jakob disease (CJD). RESULTS: We confirm only p.R47H as a risk factor for AD (odds ratio or OR = 2.19; 95% confidence interval or CI = 1.04-4.51; P = .03). p.R47H does not significantly alter risk for frontotemporal dementia (OR = 0.81), variant or sporadic CJD (OR = 1.06 95%CI = 0.66-1.69) in our cohorts. Individuals with p.R47H associated AD (n = 12) had significantly earlier symptom onset than individuals with no TREM2 variants (n = 551) (55.2 years vs. 61.7 years, P = .02). We note that heterozygous p.R47H AD is memory led and otherwise indistinguishable from "typical" sporadic AD. CONCLUSION: We find p.R47H is a risk factor for AD, but not frontotemporal dementia or prion disease.
BACKGROUND: Rare TREM2 variants are significant risk factors for Alzheimer's disease (AD). METHODS: We used next generation sequencing of the whole gene (n = 700), exon 2 Sanger sequencing (n = 2634), p.R47H genotyping (n = 3518), and genome wide association study imputation (n = 13,048) to determine whether TREM2 variants are risk factors or phenotypic modifiers in patients with AD (n = 1002), frontotemporal dementia (n = 358), sporadic (n = 2500), and variant (n = 115) Creutzfeldt-Jakob disease (CJD). RESULTS: We confirm only p.R47H as a risk factor for AD (odds ratio or OR = 2.19; 95% confidence interval or CI = 1.04-4.51; P = .03). p.R47H does not significantly alter risk for frontotemporal dementia (OR = 0.81), variant or sporadic CJD (OR = 1.06 95%CI = 0.66-1.69) in our cohorts. Individuals with p.R47H associated AD (n = 12) had significantly earlier symptom onset than individuals with no TREM2 variants (n = 551) (55.2 years vs. 61.7 years, P = .02). We note that heterozygous p.R47H AD is memory led and otherwise indistinguishable from "typical" sporadic AD. CONCLUSION: We find p.R47H is a risk factor for AD, but not frontotemporal dementia or prion disease.
Authors: H H Klünemann; B H Ridha; L Magy; J R Wherrett; D M Hemelsoet; R W Keen; J L De Bleecker; M N Rossor; J Marienhagen; H E Klein; L Peltonen; J Paloneva Journal: Neurology Date: 2005-05-10 Impact factor: 9.910
Authors: Margarita Giraldo; Francisco Lopera; Ashley L Siniard; Jason J Corneveaux; Isabelle Schrauwen; Julian Carvajal; Claudia Muñoz; Manuel Ramirez-Restrepo; Chris Gaiteri; Amanda J Myers; Richard J Caselli; Kenneth S Kosik; Eric M Reiman; Matthew J Huentelman Journal: Neurobiol Aging Date: 2013-04-09 Impact factor: 4.673
Authors: Bruno A Benitez; Breanna Cooper; Pau Pastor; Sheng-Chih Jin; Elena Lorenzo; Sebastian Cervantes; Carlos Cruchaga Journal: Neurobiol Aging Date: 2013-02-05 Impact factor: 4.673
Authors: Juha Paloneva; Tuula Manninen; Grant Christman; Karine Hovanes; Jami Mandelin; Rolf Adolfsson; Marino Bianchin; Thomas Bird; Roxana Miranda; Andrea Salmaggi; Lisbeth Tranebjaerg; Yrjö Konttinen; Leena Peltonen Journal: Am J Hum Genet Date: 2002-06-21 Impact factor: 11.025
Authors: S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo Journal: Neurology Date: 2005-05-10 Impact factor: 9.910
Authors: Sruti Rayaprolu; Bianca Mullen; Matt Baker; Timothy Lynch; Elizabeth Finger; William W Seeley; Kimmo J Hatanpaa; Catherine Lomen-Hoerth; Andrew Kertesz; Eileen H Bigio; Carol Lippa; Keith A Josephs; David S Knopman; Charles L White; Richard Caselli; Ian R Mackenzie; Bruce L Miller; Magdalena Boczarska-Jedynak; Grzegorz Opala; Anna Krygowska-Wajs; Maria Barcikowska; Steven G Younkin; Ronald C Petersen; Nilüfer Ertekin-Taner; Ryan J Uitti; James F Meschia; Kevin B Boylan; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers; Owen A Ross Journal: Mol Neurodegener Date: 2013-06-21 Impact factor: 14.195
Authors: Brian W Kunkle; Badri N Vardarajan; Adam C Naj; Patrice L Whitehead; Sophie Rolati; Susan Slifer; Regina M Carney; Michael L Cuccaro; Jeffery M Vance; John R Gilbert; Li-San Wang; Lindsay A Farrer; Christiane Reitz; Jonathan L Haines; Gary W Beecham; Eden R Martin; Gerard D Schellenberg; Richard P Mayeux; Margaret A Pericak-Vance Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Ariane H Ayer; Kevin Wojta; Eliana Marisa Ramos; Deepika Dokuru; Jason A Chen; Anna M Karydas; John D Papatriantafyllou; Dimitrios Agiomyrgiannakis; Vasiliki Kamtsadeli; Niki Tsinia; Dimitra Sali; Karen H Gylys; Federica Agosta; Massimo Filippi; Gary W Small; David A Bennett; Marla Gearing; Jorge L Juncos; Joel Kramer; Suzee E Lee; Jennifer S Yokoyama; Mario F Mendez; Helena Chui; Chris Zarow; John M Ringman; Ulkan Kilic; Gülsen Babacan-Yildiz; Allan Levey; Charles S DeCarli; Carl W Cotman; Adam L Boxer; Bruce L Miller; Giovanni Coppola Journal: Alzheimer Dis Assoc Disord Date: 2019 Oct-Dec Impact factor: 2.703
Authors: Samantha L Rosenthal; Mikhil N Bamne; Xingbin Wang; Sarah Berman; Beth E Snitz; William E Klunk; Robert A Sweet; F Yesim Demirci; Oscar L Lopez; M Ilyas Kamboh Journal: Neurobiol Aging Date: 2015-04-25 Impact factor: 4.673